Comparative Pharmacology
Head-to-head clinical analysis: ANDEMBRY versus FOLLISTIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDEMBRY versus FOLLISTIM.
ANDEMBRY vs FOLLISTIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.
Follistim (follitropin beta) is a recombinant follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and steroidogenesis.
ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.
Subcutaneous: 75-300 IU once daily for 7-21 days, adjusted based on response. Intramuscular: 75-150 IU once daily for 7-21 days.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged up to 20-25 hours in patients with moderate to severe hepatic impairment.
The terminal elimination half-life ranges from 16 to 24 hours (mean ~19 hours) following subcutaneous administration. In patients with renal impairment, half-life may be prolonged, necessitating dose adjustment.
Primarily renal excretion of unchanged drug (approximately 70-80%) and as metabolites (10-15%); biliary/fecal elimination accounts for less than 10%.
Primarily renal; approximately 70% of the dose is excreted unchanged in urine. A minor fraction (less than 5%) appears in feces via biliary elimination. The remainder is metabolized via hepatic pathways to inactive metabolites.
Category C
Category C
Gonadotropin
Gonadotropin